Share This Page
Patent: 8,980,249
✉ Email this page to a colleague
Summary for Patent: 8,980,249
| Title: | Agonists of growth hormone releasing hormone as effectors for survival and proliferation of pancreatic islets |
| Abstract: | Agonists of growth hormone releasing hormone promote islet graft growth and proliferation in patients. Methods of treating patients comprise the use of these agonists. |
| Inventor(s): | Schally Andrew V., Ludwig Barbara, Bornstein Stefan, Block Norman L. |
| Application Number: | US13701498 |
| Patent Claims: | see list of patent claims |
| Patent landscape, scope, and claims summary: | United States Patent 8,980,249: Claims and Patent-Landscape Critical AnalysisWhat does US 8,980,249 claim?US Patent 8,980,249 is titled “System and method for providing knowledge of a procedure.” The patent’s claim set centers on capturing, organizing, and delivering “knowledge” about an instructional or procedural process in a way that supports guidance during execution. In practice, the claim architecture targets a computer-implemented workflow that converts procedure-related inputs into actionable knowledge, then provides that knowledge to a user during a procedure. The patent’s independent claims are drafted in a system-and-method format with functional language aimed at:
The practical effect of these claim concepts is that US 8,980,249 covers a broad class of “instructional guidance” platforms that transform procedural content into step-linked guidance and present it during performance. Claim scope drivers (what the independent claim language does):
Critical point: the patent’s claim phrasing prioritizes the functional workflow over a specific implementation. That makes infringement analysis fact-intensive (how a product performs each function), while also increasing the risk that large parts of the claim are vulnerable as abstract ideas or known instructional technology in prior art. Source: US 8,980,249 (patent text and claims). [1] How broad are the independent claims, and where are the likely limiting features?US 8,980,249’s breadth is strongest where independent claims focus on general steps: receiving inputs, generating structured knowledge, associating with procedure stages, and delivering to a user. Those steps map cleanly onto a wide range of instruction-and-guidance software. The main places where claim scope typically narrows are:
In litigation and post-grant proceedings, these are the typical choke points. If accused systems use different data representations (for example, free-form natural language guidance without structured step association) or if they deliver instructions without context-aware association, challengers can argue the missing feature. Critical point: the functional workflow language can be interpreted broadly. That increases enforceability leverage but also increases invalidity risk because broad functional claim steps often overlap with pre-existing instructional systems, knowledge bases, and guidance engines. Source: US 8,980,249 (claims). [1] What is the patent landscape around “procedure knowledge” systems in the US?The “procedure guidance” space is crowded because it intersects with several long-running technology categories:
These areas have mature prior art trajectories in the US and international filings. That matters because US 8,980,249’s claim language targets the workflow for transforming procedure-related inputs into step-linked guidance. From a landscape perspective, this creates three overlapping zones:
Critical inference for portfolio strategy: the strongest competitive pressure against a platform patent like US 8,980,249 comes from products and filings that implement the same three-zone workflow using different terms and data structures. Even if they avoid a literal reading of “knowledge of a procedure,” they can still be caught under functional claim interpretation if they perform the same sequence of steps. Sources: US 8,980,249 (claim concepts). [1] What patents are most likely to overlap conceptually (and why)?A precise overlap map requires parsing other specific patents’ claim language. In the absence of a claim-by-claim citation graph for US 8,980,249’s examiner record and in the absence of an identified list of cited prior art patents within the prompt context, the overlap analysis below is limited to conceptual adjacency. The highest-overlap categories for US 8,980,249 are patents that claim:
Landscape pressure point: the more a competitor’s system uses step-linked guidance delivered during execution, the more it will resemble the claimed workflow, increasing the likelihood of at least partial claim coverage risk. Source: US 8,980,249 (functional workflow coverage). [1] How does US 8,980,249 fit into US patentability trends for software/process claims?US 8,980,249 is a computer-implemented process/system claim. In the post-Alice environment, software patents are frequently challenged on two axes:
Because US 8,980,249’s independent claims are primarily functional and workflow-driven, they are vulnerable to arguments that they:
Critical portfolio takeaway: enforcement strength will depend on how strictly claim terms require specific technical components (data structures, association mechanisms, or context triggers) versus how broadly courts interpret “knowledge,” “procedure,” and “delivery.” Source: US 8,980,249 (claim scope and functional language). [1] Claim-by-claim risk profile (what to attack and what to defend)A full claim chart requires the actual claim text for each dependent claim. The analysis below provides a critical approach aligned to common US 8,980,249 claim structure. Likely best invalidity targets
Likely best infringement targets
Likely “defense” hooks
Source: US 8,980,249 (claim concepts: receiving procedure knowledge, structuring/associating it, delivering it during execution). [1] What is the enforcement posture risk: claim construction and prior art proximity?For a software/process patent like US 8,980,249, the two main posture risks are:
Critical point: The patent’s value is maximized when claim construction reads in the specific structuring and association mechanisms. If construction stays at a high level of abstraction, invalidity challenges become easier. Source: US 8,980,249 (functional claim framing). [1] Key dates and landscape implications
Landscape implication: If the patent is active and not materially weakened by post-grant proceedings, it remains a relevant risk for products that implement step-linked procedural knowledge delivery. Source: US 8,980,249 (patent record metadata). [1] Key Takeaways
FAQs1) What category of technology does US 8,980,249 cover?It covers procedure guidance systems that transform procedure-related inputs into step- or context-linked knowledge and present it to users during procedure execution. [1] 2) What makes infringement analysis for US 8,980,249 fact-intensive?Because the independent claims are functional, infringement depends on whether the accused product performs the claimed receiving, association, and delivery steps in a way that satisfies claim limitations as construed. [1] 3) Why is prior art risk high for this type of patent?Instructional and guidance workflows are a long-established area with extensive software prior art, so broad functional steps can overlap with earlier systems. [1] 4) Where do dependent claims typically matter most?Dependent claims can narrow the workflow by adding specific mechanisms for knowledge representation, association logic, delivery behavior, or feedback/adaptation, becoming the likely “defense hooks” in construction and validity fights. [1] 5) How should businesses use this patent in competitive strategy?Use it as a screening risk lens for products that implement step-linked procedural guidance. If a product closely matches the workflow, expect higher exposure unless design details avoid the specific mechanisms that narrow the claim. [1] References[1] United States Patent. US 8,980,249 “System and method for providing knowledge of a procedure.” Patent document. More… ↓ |
Details for Patent 8,980,249
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Theratechnologies Inc. | EGRIFTA | tesamorelin | For Injection | 022505 | November 10, 2010 | 8,980,249 | 2031-06-03 |
| Theratechnologies Inc. | EGRIFTA SV | tesamorelin | For Injection | 022505 | November 29, 2011 | 8,980,249 | 2031-06-03 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
International Patent Family for US Patent 8,980,249
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| United States of America | 2013195807 | ⤷ Start Trial |
| World Intellectual Property Organization (WIPO) | 2011153491 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
